Lifecare ASA

Regulatory Filings • Mar 6, 2024

LIFE: Poster presentations at ATTD 2024 in Firenze

LIFE: Poster presentations at ATTD 2024 in Firenze

Today starts the 17th International Conference on Advanced Technologies &

Treatments for Diabetes (ATTD 2024) in Firenze. Lifecare will be represented

at the conference and have been accepted to present three poster

presentations.

ATTD is a leading international diabetes technology forum where clinicians,

diabetes care providers, researchers, industries, start-up, investors,

reimbursement authorities, regulators and people with diabetes, assemble with

the goal to ameliorate the care of people with diabetes at the fastest

possible pace.

-- I am very humbled to be invited to this conference once again. This is

undeniably a very attractive arena to present our innovative diabetes

technology, says the CSO Prof. Andreas Pfützner at Lifecare. During the ATTD

in Italy he will present no less than three poster presentations.

The first presentation is about last year's first human pilot study of the

Sencell sensor. In addition, Lifecare has developed an in-vitro test method to

continuously and dynamically investigate potential interferents. Little is

known regarding the potential interference of drugs or nutritional substances

on commercially available CGM sensors. In this matter Prof. Dr. Dr. Pfützner

will present two of Lifecare's testing results on dynamic interference. One

presentation regarding the Libre 3 continuous glucose monitoring device in

comparison to Libre 2 and one presentation about the Dexcom G7 continuous

monitoring device in comparison to Dexcom G6.

-- Naturally, there is recognition for being present in such a forum, but it

also comes as a result of growing interests for our sensor technology. We

pursue a groundbreaking product development. Last year's progress due to proof

of concept and accuracy of the Sencell and the longevity experiment that

concluded with six months operational lifetime, obviously creates a certain

curiosity, says Pfützner.

-- At the conference in Firenze, we have the opportunity to meet an audience

that includes diabetes technology experts and other leading scientists such as

clinicians active in the field of endocrinology and metabolism, pediatrics and

family medicine, as well as scientists working in pharmaceutical and medicinal

product companies. They come from all over the world, from industry, academia

and primary care institutions, states Pfützner.

The purpose of the ATTD meeting is to highlight innovative technologies and

treatments in diabetes management. It assembles developers of new technologies

with diabetes care professionals and caretakers, researchers, industries,

startup companies, investors, reimbursement authorities and regulators, as

well as people with diabetes. Distinguished international professionals

discuss and disseminate information on the latest technologies and treatments

in our field.

About us

Lifecare AS is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,

asle.wingsternes@lifecare.no, +47 41 61 42 52